Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 20/20 | 0.66 |
| ▸ | MME | P08473 | 12/20 | 0.66 |
| ▸ | AGTR2 | P50052 | 9/20 | 0.66 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257583 | 0.92 | MME (0.79) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL1257577 | 0.92 | MME (0.79) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL16146294 | 0.92 | AGTR1 (0.66) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL16147190 | 0.88 | MME (0.56) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL1099412 | 0.86 | MME (0.81) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL1258819 | 0.86 | MME (0.81) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL1099415 | 0.86 | MME (0.81) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL16146703 | 0.86 | MME (0.69) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL15121593 | 0.85 | AGTR1 (0.66) | AGTR1MMEAGTR2ECE1 | |
| SCHEMBL16147188 | 0.85 | MME (0.58) | AGTR1MMEAGTR2ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012485-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303222-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 13/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.